These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 14600639)

  • 21. Anticoagulation period in idiopathic venous thromboembolism. How long is enough?
    Farraj RS
    Saudi Med J; 2004 Jul; 25(7):848-51. PubMed ID: 15235686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Warfarin prophylaxis for orthopaedic venous thromboembolic disease.
    Pellegrini VD
    Instr Course Lect; 2002; 51():491-8. PubMed ID: 12064139
    [No Abstract]   [Full Text] [Related]  

  • 23. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice.
    Balibrea JL; Altimiras J; Larruzea I; Gómez-Outes A; Martínez-González J; Rocha E;
    Int J Surg; 2007 Apr; 5(2):114-9. PubMed ID: 17448976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term anticoagulation prophylaxis following acute thromboembolism.
    Hyers TM
    Dis Mon; 2005; 51(2-3):158-65. PubMed ID: 15900268
    [No Abstract]   [Full Text] [Related]  

  • 25. Standard-intensity vs low-dose anticoagulation for long-term management of patients with venous thromboembolism.
    Lazo-Langner A; Kovacs MJ
    Clin Adv Hematol Oncol; 2005 Nov; 3(11):877-9. PubMed ID: 16491633
    [No Abstract]   [Full Text] [Related]  

  • 26. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low dose.
    Shrivastava S; Ridker PM
    Clin Adv Hematol Oncol; 2005 Nov; 3(11):880-1. PubMed ID: 16491634
    [No Abstract]   [Full Text] [Related]  

  • 28. Venous thromboembolism: risk factors for recurrence.
    Zhu T; Martinez I; Emmerich J
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):298-310. PubMed ID: 19228602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prophylaxis against venous thromboembolism in acutely ill medical patients: an observational study.
    Peterman CM; Kolansky DM; Spinler SA
    Pharmacotherapy; 2006 Aug; 26(8):1086-90. PubMed ID: 16863485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
    Nishioka J; Goodin S
    J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of low-dose warfarin as prophylaxis for central venous catheter thrombosis in patients with cancer: a meta-analysis.
    Rawson KM; Newburn-Cook CV
    Oncol Nurs Forum; 2007 Sep; 34(5):1037-43. PubMed ID: 17878131
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update in the treatment of venous thromboembolism.
    Garcia DA; Spyropoulos AC
    Semin Respir Crit Care Med; 2008 Feb; 29(1):40-6. PubMed ID: 18302085
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long term anticoagulation of idiopathic venous thromboembolism: do we have the answers?
    Goldhaber S
    Clin Adv Hematol Oncol; 2003 May; 1(5):276-7. PubMed ID: 16224420
    [No Abstract]   [Full Text] [Related]  

  • 34. Deep-vein thrombosis in malignancy: how long should patients be treated, and with what?
    Merli GJ
    Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S27-34. PubMed ID: 19530157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Initiating warfarin therapy: 5 mg versus 10 mg.
    Eckhoff CD; Didomenico RJ; Shapiro NL
    Ann Pharmacother; 2004 Dec; 38(12):2115-21. PubMed ID: 15522981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-dose warfarin for the prevention of central line-associated thromboses in children with malignancies--a randomized, controlled study.
    Ruud E; Holmstrøm H; De Lange C; Hogstad EM; Wesenberg F
    Acta Paediatr; 2006 Sep; 95(9):1053-9. PubMed ID: 16938749
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of combined modality prophylaxis including short-duration warfarin to prevent venous thromboembolism after total hip arthroplasty.
    Keeney JA; Clohisy JC; Curry MC; Maloney WJ
    J Arthroplasty; 2006 Jun; 21(4):469-75. PubMed ID: 16781396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor.
    Kearon C; Ginsberg JS; Anderson DR; Kovacs MJ; Wells P; Julian JA; Mackinnon B; Demers C; Douketis J; Turpie AG; Van Nguyen P; Green D; Kassis J; Kahn SR; Solymoss S; Desjardins L; Geerts W; Johnston M; Weitz JI; Hirsh J; Gent M;
    J Thromb Haemost; 2004 May; 2(5):743-9. PubMed ID: 15099280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of thrombosis in the cancer patient.
    Andrea N; Ansell J
    J Support Oncol; 2003; 1(4):235-8, 240-2; discussion 239-40, 243-5. PubMed ID: 15334865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism.
    Johnston JA; Brill-Edwards P; Ginsberg JS; Pauker SG; Eckman MH
    Am J Med; 2005 May; 118(5):503-14. PubMed ID: 15866253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.